Pancreatic cancer remains one of oncology's most lethal diagnoses, with five-year survival rates still hovering near 12% for all stages combined. The absence of clear, unified guidance on when and how to deploy radiation therapy has long contributed to wide variability in care — a gap this new consensus effort directly addresses by establishing condition-specific recommendations across the full disease spectrum.
The American Society for Radiation Oncology convened a multidisciplinary task force to systematically evaluate radiation therapy's role across five clinical scenarios: resectable, borderline resectable, locally advanced, metastatic, and symptomatic disease. For resectable pancreatic cancer, radiation is conditionally recommended in both preoperative and postoperative settings — a notably measured endorsement reflecting genuine uncertainty in the evidence base. The strongest recommendations emerge for borderline resectable disease, where preoperative radiation is now formally backed, and for locally advanced disease, where definitive radiation therapy receives an unqualified recommendation. Dose-fractionation guidance distinguishes between preoperative contexts, where both conventional fractionation and moderate hypofractionation are endorsed, and postoperative use, where conventional fractionation alone is recommended.
What distinguishes this guideline from prior institutional protocols is its systematic grading of evidence quality alongside recommendation strength — a methodology that forces transparency about where data is robust versus where consensus fills evidentiary gaps. The mandate for multidisciplinary evaluation across all patient categories reflects the field's recognition that radiation decisions cannot be made in isolation from surgical and systemic therapy planning. From a broader landscape perspective, these guidelines arrive as stereotactic body radiation therapy and MR-guided adaptive radiotherapy are reshaping delivery precision for pancreatic targets — techniques implicitly addressed in the planning and delivery recommendations. The guideline's conditional language for resectable disease is analytically honest: randomized trial data in this setting remains sparse and inconsistent. Clinicians and patients can now reference a structured, evidence-tiered framework, though the real-world impact will depend on how consistently multidisciplinary tumor boards integrate these recommendations into individualized care pathways.